Phospholipid composition of Pneumocystis carinii carinii and effects of methylprednisolone immunosuppression on rat lung lipids
- PMID: 7890386
- PMCID: PMC173148
- DOI: 10.1128/iai.63.4.1286-1290.1995
Phospholipid composition of Pneumocystis carinii carinii and effects of methylprednisolone immunosuppression on rat lung lipids
Abstract
The phospholipid class composition of Pneumocystis carinii carinii freshly isolated from infected lungs generally resembled that of the host lung, suggesting that the parasite scavenges lung alveolar lipids. However, subtle quantitative differences were demonstrated, indicating that the pathogen has the metabolic capacity to de novo synthesize, or at least tailor, its lipids. The concentration of phosphatidylcholine, the major lung surfactant lipid, in the organism was lower than that in lungs of normal and immunosuppressed uninfected rats, and the concentration of phosphatidylinositol was higher. Phosphonolipids were not detected in the organism by chemical analysis and nuclear magnetic resonance spectrometry. The immunosuppressive regimen alone caused increases in both surfactant protein A and the lipid content of the whole lung. The lungs of rats that were subjected to corticosteroid immunosuppression and had heavy parasite loads had dramatically elevated surfactant protein A levels, whereas the lipid contents of these lungs were not different from lipid contents in whole lungs of immunosuppressed uninfected rats. P. carinii was found to concentrate lipids, indicating that a large amount of the lipids in the whole infected rat lung was within the parasites residing in the organ. These observations have important implications relevant to the use of corticosteroid therapy for P. carinii pneumonitis.
Similar articles
-
The lipids of Pneumocystis carinii.Clin Microbiol Rev. 1998 Jan;11(1):27-41. doi: 10.1128/CMR.11.1.27. Clin Microbiol Rev. 1998. PMID: 9457427 Free PMC article. Review.
-
Fatty acid composition of the major phospholipids of Pneumocystic carinii: comparison with those in the lungs of normal and methylprednisolone-immunosuppressed rats.Infect Immun. 1996 Apr;64(4):1407-12. doi: 10.1128/iai.64.4.1407-1412.1996. Infect Immun. 1996. PMID: 8606108 Free PMC article.
-
Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat.Eur Respir J. 1996 Mar;9(3):565-70. doi: 10.1183/09031936.96.09030565. Eur Respir J. 1996. PMID: 8730021
-
Composition of Pneumocystis carinii neutral lipids and identification of coenzyme Q10 as the major ubiquinone homolog.J Eukaryot Microbiol. 1996 May-Jun;43(3):165-70. doi: 10.1111/j.1550-7408.1996.tb01385.x. J Eukaryot Microbiol. 1996. PMID: 8640186
-
Alveolar macrophage and glycoprotein responses to Pneumocystis carinii.Semin Respir Infect. 1998 Dec;13(4):339-47. Semin Respir Infect. 1998. PMID: 9872631 Review.
Cited by
-
C27 to C32 sterols found in Pneumocystis, an opportunistic pathogen of immunocompromised mammals.Lipids. 2000 Mar;35(3):317-24. doi: 10.1007/s11745-000-0528-8. Lipids. 2000. PMID: 10783009
-
The lipids of Pneumocystis carinii.Clin Microbiol Rev. 1998 Jan;11(1):27-41. doi: 10.1128/CMR.11.1.27. Clin Microbiol Rev. 1998. PMID: 9457427 Free PMC article. Review.
-
Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study.Thorax. 2003 Jul;58(7):594-7. doi: 10.1136/thorax.58.7.594. Thorax. 2003. PMID: 12832674 Free PMC article.
-
Sterol metabolism in the opportunistic pathogen Pneumocystis: advances and new insights.Lipids. 2004 Aug;39(8):753-61. doi: 10.1007/s11745-004-1292-5. Lipids. 2004. PMID: 15638243 Review.
-
Metabolic modelling as a powerful tool to identify critical components of Pneumocystis growth medium.PLoS Comput Biol. 2024 Oct 28;20(10):e1012545. doi: 10.1371/journal.pcbi.1012545. eCollection 2024 Oct. PLoS Comput Biol. 2024. PMID: 39466836 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources